SEP 4, 2026 · JOURNAL ARTICLE
Development and internal validation of prognostic nomograms for overall and breast cancer-specific survival in de novo stage IV HER2-positive breast cancer
Biomolecules and Biomedicine
A methodologically sound single-centre internal validation study of prognostic nomograms with good discrimination (C-index 0.74–0.76) in a contemporary HER2-positive metastatic cohort, but limited by lack of specific treatment annotation and short median follow-up relative to the 5-year outcome estimates.
Reported
Sample size (total)1516
Training cohort1061
Validation cohort455